Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

OBJECTIVES: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission. METHODS: This phase 2, double-blind, placebo-controlled trial enroll...

Descripción completa

Detalles Bibliográficos
Autores principales: Cid, Maria C, Unizony, Sebastian H, Blockmans, Daniel, Brouwer, Elisabeth, Dagna, Lorenzo, Dasgupta, Bhaskar, Hellmich, Bernhard, Molloy, Eamonn, Salvarani, Carlo, Trapnell, Bruce C, Warrington, Kenneth J, Wicks, Ian, Samant, Manoj, Zhou, Teresa, Pupim, Lara, Paolini, John F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Vasculitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995812/
https://www.ncbi.nlm.nih.gov/pubmed/35264321
http://dx.doi.org/10.1136/annrheumdis-2021-221865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995812/
https://www.ncbi.nlm.nih.gov/pubmed/35264321
http://dx.doi.org/10.1136/annrheumdis-2021-221865

Ejemplares similares